Eli Lilly and Company $LLY Shares Sold by Amplius Wealth Advisors LLC

Amplius Wealth Advisors LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 7.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,424 shares of the company’s stock after selling 122 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,110,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Wellington Management Group LLP lifted its holdings in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after acquiring an additional 682,203 shares during the period. Finally, Nuveen LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 3.5%

Eli Lilly and Company stock opened at $842.28 on Friday. The stock has a market cap of $797.18 billion, a PE ratio of 55.05, a P/E/G ratio of 1.21 and a beta of 0.47. The stock has a 50-day moving average price of $777.69 and a 200 day moving average price of $770.84. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LLY shares. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. HSBC lifted their price target on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, JPMorgan Chase & Co. cut their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $936.47.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.